Navigation Links
NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
Date:11/9/2009

a> * FDA has yet to approve the name Fludase.

DISCLOSURE NOTICE:

This release contains forward-looking information about the research and development program of NexBio and the potential efficacy of product candidates that might result from programs that involve substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to permit the clinical investigation of or approve any drug applications that may result from the programs as well as their decisions regarding labeling and other matters that could affect the commercial potential of product candidates that may result from the program; and competitive developments.

SOURCE NexBio, Inc.


'/>"/>
SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
2. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
3. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... biopharmaceutical contract development and manufacturing organization (CMO) announced ... Pharmaceuticals, Inc., an oncology company focused on the ... cancer, to manufacture the anti-prostate specific membrane antigen ... product candidate. Under the agreement the antibody ...
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... measuring vibrational motion of a single molecule with a ... a single molecule differs from the behaviour of larger ... the University of California, Irvine, where post-doctoral researcher Eero ... visiting fellow under professor Vartkess A. Apkarian, whose team ... by Professor Eric O. Potma. The results of the ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2
... Bulletin Board: TBIO ) today announced that ... Director for Laboratory Services.  In this newly created position ... vision and managing the day-to-day operations of Transgenomic,s Molecular ... to Transgenomic nearly 20 years of genetics experience in ...
... 21 Sermo ( http://www.sermo.com ), the largest online ... titled, " Physician Participation in the ESA REMS Program ... in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk evaluation and ... results, 83% of Hematologists/Oncologists view the ESA REMS program ...
... HIGHLIGHTS:   2010 Results (all percentages are ... reported sales increased 5% to $563 million. Excluding foreign currency exchange ... for SAFC (Fine Chemicals) and Research Products increased 12% and 3%, ... and 5%, respectively. Q3 2010 reported diluted EPS ...
Cached Biology Technology:Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services 2Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services 3Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services 4Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 12
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... State University have developed a novel and versatile modeling ... for creating new materials as well as for studying ... allows us to model much larger and more complex ... says Nan Li, lead author of a paper on ... Department of Materials Science and Engineering. "This is a ...
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... Engineering Conferences International (ECI) ( info@engconfintl.org ... XII Conference ( http://www.engconfintl.org/10ac.html ) are proud ... the winner of the 2010 Cell Culture ... Professor of Chemical and Biomolecular Engineering, at ...
... the Iberian Peninsula usually exceed the protection threshold established by ... according to data gathered between 2000 and 2005 by four ... Doana National Park. The limits established to protect human ... usually exceeded from April onwards, especially during the summer, in ...
... Langone Medical Center researchers have developed a powerful new method ... genes and examine how the process goes wrong in cancer ... research and described in the April 9 issue of ... DNA, a process required for gene activation. "The ...
Cached Biology News:Michael Betenbaugh wins 2010 Cell Culture Engineering award 2Ozone levels tend to be above recommended levels at this time of year in South West Spain 2Powerful new method allows scientists to probe gene activation 2
... is a four-channel general purpose laboratory amplifier. It ... sources which may have a large common-mode level ... a high gain/low noise amplifier, an input coupling ... offset control. A control knob sets the amplifier ...
... Pro-OpioMelanoCortin (POMC) has long been ... prime precursor to a multiplicity of ... (-LPH), -endorphin, Alpha-Melanocyte Stimulating Hormone (a-MSH) ... very well-conserved molecule, being found in ...
...
...
Biology Products: